Annis Gardner Whiting Capital Advisors LLC Raises Position in Repligen Co. (NASDAQ:RGEN)

Annis Gardner Whiting Capital Advisors LLC lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 34.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 805 shares of the biotechnology company’s stock after purchasing an additional 205 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in Repligen were worth $145,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Retirement Systems of Alabama boosted its holdings in Repligen by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock worth $11,693,000 after buying an additional 288 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Repligen by 1.5% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after purchasing an additional 159 shares during the period. International Assets Investment Management LLC boosted its holdings in Repligen by 18,449.1% in the 4th quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after purchasing an additional 58,299 shares during the period. American Century Companies Inc. boosted its holdings in Repligen by 97.5% in the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the period. Finally, Los Angeles Capital Management LLC bought a new position in Repligen in the 4th quarter valued at $965,000. 97.64% of the stock is owned by institutional investors.

Insider Activity

In other news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares in the company, valued at $27,456,162.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares in the company, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Insiders have sold a total of 45,669 shares of company stock worth $8,416,847 over the last 90 days. 1.20% of the stock is currently owned by insiders.

Repligen Stock Down 1.7 %

RGEN traded down $2.80 during midday trading on Thursday, reaching $162.33. The company’s stock had a trading volume of 142,681 shares, compared to its average volume of 521,795. The firm has a market capitalization of $9.07 billion, a price-to-earnings ratio of 651.31, a PEG ratio of 5.58 and a beta of 1.03. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The stock’s 50-day moving average is $174.69 and its 200-day moving average is $177.25.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter last year, the company posted $0.64 EPS. Repligen’s revenue for the quarter was down 17.1% compared to the same quarter last year. As a group, research analysts expect that Repligen Co. will post 1.46 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on RGEN shares. KeyCorp upped their target price on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. lowered their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, Stifel Nicolaus boosted their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $197.75.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.